Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02136134




Registration number
NCT02136134
Ethics application status
Date submitted
1/05/2014
Date registered
12/05/2014
Date last updated
13/03/2024

Titles & IDs
Public title
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Scientific title
Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma
Secondary ID [1] 0 0
2014-000255-85
Secondary ID [2] 0 0
CR103995
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Daratumumab
Treatment: Drugs - VELCADE (Bortezomib)
Treatment: Drugs - Dexamethasone

Experimental: Daratumumab+VELCADE+dexamethasone - Daratumumab, VELCADE and dexamethasone

Active comparator: VELCADE+dexamethasone - VELCADE and dexamethasone.


Treatment: Drugs: Daratumumab
Daratumumab will be administered as an IV infusion or 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter. As per protocol amendment-6 participants receiving treatment with daratumumab IV will have the option to switch to daratumumab SC 1800 mg on Day 1 of any cycle, at the discretion of the investigator.

Treatment: Drugs: VELCADE (Bortezomib)
VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.

Treatment: Drugs: Dexamethasone
Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival (PFS)
Timepoint [1] 0 0
From the date of randomization to either progressive disease or death, whichever occurred first (approximately 1 year 4 months)
Secondary outcome [1] 0 0
Time to Disease Progression (TTP)
Timepoint [1] 0 0
From the date of randomization to the date of first documented evidence of progression or death due to PD whichever occurred first (approximately 6 years 9 months)
Secondary outcome [2] 0 0
Percentage of Participants With a Very Good Partial Response (VGPR) or Better
Timepoint [2] 0 0
Up to disease progression (approximately 6 years 9 months)
Secondary outcome [3] 0 0
Overall Response Rate (ORR)
Timepoint [3] 0 0
Up to disease progression (approximately 6 years 9 months)
Secondary outcome [4] 0 0
Percentage of Participants With Negative Minimal Residual Disease (MRD)
Timepoint [4] 0 0
Up to disease progression (approximately 6 years 9 months)
Secondary outcome [5] 0 0
Overall Survival (OS)
Timepoint [5] 0 0
Up to 6 years 9 months

Eligibility
Key inclusion criteria
* Must have had documented multiple myeloma
* Must have received at least 1 prior line of therapy for multiple myeloma
* Must have had documented evidence of progressive disease as defined based on Investigator's determination of response of International Myeloma Working Group (IMWG) criteria on or after their last regimen
* Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2
* Must have achieved a response (partial response [PR] or better based on investigator's determination of response by the IMWG criteria) to at least 1 prior regimen in the past
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Has received daratumumab or other anti-CD38 therapies previously
* Is refractory to VELCADE or another PI, like ixazomib and carfilzomib (had progression of disease while receiving VELCADE therapy or within 60 days of ending VELCADE therapy or another PI therapy, like ixazomib and carfilzomib
* Is intolerant to VELCADE (ie, discontinued due to any adverse event while on VELCADE treatment)
* Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day [mg/day] for a maximum of 4 days) before treatment. A list of anti-myeloma treatments with the corresponding pharmacokinetic half-lives is provided in the Site Investigational Product Procedures Manual (IPPM).
* Has a history of malignancy (other than multiple myeloma) within 3 years before the date of randomization
* Has any concurrent medical condition or disease (eg, active systemic infection) that is likely to interfere with study procedures

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/08/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
12/01/2024
Sample size
Target
Accrual to date
Final
498
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Concord
Recruitment hospital [3] 0 0
- Fitzroy
Recruitment hospital [4] 0 0
- Hobart
Recruitment hospital [5] 0 0
- Melbourne
Recruitment hospital [6] 0 0
- Nedlands
Recruitment hospital [7] 0 0
- Woodville South
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Concord
Recruitment postcode(s) [3] 0 0
- Fitzroy
Recruitment postcode(s) [4] 0 0
- Hobart
Recruitment postcode(s) [5] 0 0
- Melbourne
Recruitment postcode(s) [6] 0 0
- Nedlands
Recruitment postcode(s) [7] 0 0
- Woodville South
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Oregon
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Rhode Island
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
Brazil
State/province [17] 0 0
Barretos
Country [18] 0 0
Brazil
State/province [18] 0 0
Porto Alegre
Country [19] 0 0
Brazil
State/province [19] 0 0
Salvador
Country [20] 0 0
Brazil
State/province [20] 0 0
Sao Paulo
Country [21] 0 0
Brazil
State/province [21] 0 0
São Paulo
Country [22] 0 0
Czechia
State/province [22] 0 0
Brno
Country [23] 0 0
Czechia
State/province [23] 0 0
Hradec Kralove
Country [24] 0 0
Czechia
State/province [24] 0 0
Ostrava-Poruba
Country [25] 0 0
Czechia
State/province [25] 0 0
Praha 10
Country [26] 0 0
Czechia
State/province [26] 0 0
Praha 2
Country [27] 0 0
Germany
State/province [27] 0 0
Bamberg
Country [28] 0 0
Germany
State/province [28] 0 0
Berlin
Country [29] 0 0
Germany
State/province [29] 0 0
Duesseldorf
Country [30] 0 0
Germany
State/province [30] 0 0
Freiburg
Country [31] 0 0
Germany
State/province [31] 0 0
Göttingen
Country [32] 0 0
Germany
State/province [32] 0 0
Hamburg
Country [33] 0 0
Germany
State/province [33] 0 0
Mainz
Country [34] 0 0
Germany
State/province [34] 0 0
München
Country [35] 0 0
Germany
State/province [35] 0 0
Stuttgart
Country [36] 0 0
Germany
State/province [36] 0 0
Tübingen
Country [37] 0 0
Germany
State/province [37] 0 0
Ulm
Country [38] 0 0
Germany
State/province [38] 0 0
Würzburg
Country [39] 0 0
Hungary
State/province [39] 0 0
Budapest
Country [40] 0 0
Hungary
State/province [40] 0 0
Debrecen
Country [41] 0 0
Hungary
State/province [41] 0 0
Gyor
Country [42] 0 0
Hungary
State/province [42] 0 0
Pecs
Country [43] 0 0
Hungary
State/province [43] 0 0
Veszprém
Country [44] 0 0
Korea, Republic of
State/province [44] 0 0
Busan
Country [45] 0 0
Korea, Republic of
State/province [45] 0 0
Hwasun
Country [46] 0 0
Korea, Republic of
State/province [46] 0 0
Seoul
Country [47] 0 0
Korea, Republic of
State/province [47] 0 0
Suwon
Country [48] 0 0
Korea, Republic of
State/province [48] 0 0
Ulsan
Country [49] 0 0
Mexico
State/province [49] 0 0
Huixquilucan
Country [50] 0 0
Mexico
State/province [50] 0 0
Monterrey
Country [51] 0 0
Netherlands
State/province [51] 0 0
Alkmaar
Country [52] 0 0
Netherlands
State/province [52] 0 0
Amersfoort
Country [53] 0 0
Netherlands
State/province [53] 0 0
Den Haag
Country [54] 0 0
Netherlands
State/province [54] 0 0
Dordrecht
Country [55] 0 0
Netherlands
State/province [55] 0 0
Groningen
Country [56] 0 0
Netherlands
State/province [56] 0 0
Leiden
Country [57] 0 0
Netherlands
State/province [57] 0 0
Maastricht
Country [58] 0 0
Netherlands
State/province [58] 0 0
Nijmegen
Country [59] 0 0
Poland
State/province [59] 0 0
Chorzów
Country [60] 0 0
Poland
State/province [60] 0 0
Katowice
Country [61] 0 0
Poland
State/province [61] 0 0
Krakow
Country [62] 0 0
Poland
State/province [62] 0 0
Poznan
Country [63] 0 0
Poland
State/province [63] 0 0
Warszawa
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Krasnodar
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Moscow
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Nizhny Novgorod
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Penza
Country [68] 0 0
Russian Federation
State/province [68] 0 0
Pyatigorsk
Country [69] 0 0
Russian Federation
State/province [69] 0 0
Ryazan
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Samara
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Sochi
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Syktyvkar
Country [73] 0 0
Spain
State/province [73] 0 0
Madrid
Country [74] 0 0
Spain
State/province [74] 0 0
Salamanca
Country [75] 0 0
Spain
State/province [75] 0 0
San Sebastian de los Reyes
Country [76] 0 0
Spain
State/province [76] 0 0
Toledo
Country [77] 0 0
Spain
State/province [77] 0 0
Valencia
Country [78] 0 0
Sweden
State/province [78] 0 0
Linkoping
Country [79] 0 0
Sweden
State/province [79] 0 0
Lulea
Country [80] 0 0
Sweden
State/province [80] 0 0
Lund
Country [81] 0 0
Sweden
State/province [81] 0 0
Orebro
Country [82] 0 0
Sweden
State/province [82] 0 0
Sundsvall
Country [83] 0 0
Sweden
State/province [83] 0 0
Umea
Country [84] 0 0
Sweden
State/province [84] 0 0
Uppsala
Country [85] 0 0
Sweden
State/province [85] 0 0
Västerås
Country [86] 0 0
Turkey
State/province [86] 0 0
Ankara
Country [87] 0 0
Turkey
State/province [87] 0 0
Istanbul
Country [88] 0 0
Turkey
State/province [88] 0 0
Izmir
Country [89] 0 0
Turkey
State/province [89] 0 0
Kayseri
Country [90] 0 0
Turkey
State/province [90] 0 0
Kocaeli
Country [91] 0 0
Turkey
State/province [91] 0 0
Malatya
Country [92] 0 0
Ukraine
State/province [92] 0 0
Cherkasy
Country [93] 0 0
Ukraine
State/province [93] 0 0
Dnepropetrovsk
Country [94] 0 0
Ukraine
State/province [94] 0 0
Ivano-Frankivsk
Country [95] 0 0
Ukraine
State/province [95] 0 0
Kiev
Country [96] 0 0
Ukraine
State/province [96] 0 0
Lviv
Country [97] 0 0
Ukraine
State/province [97] 0 0
Poltava
Country [98] 0 0
Ukraine
State/province [98] 0 0
Vinnitsa
Country [99] 0 0
Ukraine
State/province [99] 0 0
Zaporizhzhya

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT02136134